LifeVantage First Quarter Revenue Edges Up as LoveBiome Integration Exceeds Expectations

SALT LAKE CITY, UT -- November 4, 2025

LifeVantage Corporation reported first fiscal quarter revenue of 47.6 million dollars for the period ended September 30, 2025, up 0.7 percent from a year earlier and up about 0.3 percent excluding currency effects. Revenue in the Americas rose 0.8 percent and revenue in Asia Pacific and Europe rose 0.4 percent, but fell 1.4 percent in constant currency.

Net income was 0.17 dollars per diluted share, compared with 0.14 dollars a year earlier, and adjusted earnings per share were 0.18 dollars, compared with 0.15 dollars. Adjusted EBITDA declined to 3.9 million dollars from 4.4 million dollars. The company declared a quarterly cash dividend of 0.045 dollars per share and reiterated its fiscal 2026 guidance of revenue of 225 million to 240 million dollars, adjusted EBITDA of 23 million to 26 million dollars and adjusted earnings per share of 1.00 to 1.15 dollars, with revenue expected to be higher in the second half of the fiscal year.

"The integration of LoveBiome's passionate consultant community along with their flagship P84 product is already exceeding expectations and momentum is building across our business," said President and Chief Executive Steve Fife, who called the quarter a pivotal milestone that positions the company at the intersection of natural GLP-1 activation and microbiome health.